ArticleFrontiers in medicine2026
Case Report: Perifoveal exudative vascular anomalous complex with secondary fundus hemorrhage.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Perifoveal exudative vascular anomalous complex (PEVAC) is a rare macular disorder characterized by isolated, circular aneurysmal lesions surrounding the fovea centralis, typically occurring in otherwise healthy patients without retinal inflammation or vascular abnormalities. This study aimed to highlight a rare case of PEVAC with secondary fundus hemorrhage. Case presentation: This study reports the case of a 44-year-old Chinese woman with PEVAC complicated by secondary fundus hemorrhage. The PEVAC diagnosis was confirmed through fundus fluorescein angiography, indocyanine green angiography, optical coherence tomography, and optical coherence tomography angiography. After intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment, the patient experienced marked improvement in visual acuity, reaching 20/20. Conclusion: The case presented in this study underscores that PEVAC may lead to the rupture and hemorrhage of secondary lesions. Gradual improvement in the patient's vision was achieved through intravitreal anti-VEGF injections. This study found that the menstrual cycle in women may influence disease progression. However, the relationship between the menstrual cycle and disease progression remains unclear.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.